CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 601–700 of 1,010
Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
Qin, L., Waseem, T. C., Sahoo, A., Bieerkehazhi, S., Zhou, H., Galkina, E. V., & Nurieva, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01884 · Cited by 95
“In fact, a Treg-specific deletion of CTLA4 recapitulates the phenotype of germline CTLA4 KO mice including increase in antibody production, indicating the role of CTLA4 in Tregs to control B cell responses (96).”
BackgroundJavadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 107
Swainson, L. A., Mold, J. E., Bajpai, U. D., & McCune, J. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903943 · Cited by 101
“The use of CD25-depleted PBMCs provides a more physiologically represen- tative mixture of cells, including APCs, that can directly or indirectly influence or mediate Treg function (2, 13–16).”
InfluentialImmune checkpoint inhibitors in renal cell carcinoma
Ross, K., & Jones, R. J. (2017) · Clinical Science · doi:10.1042/cs20160894 · Cited by 105
Herzog, B. H., Baer, J. M., Borcherding, N. C., Kingston, N. L., Belle, J. I., Knolhoff, B. L., Hogg, G. D., Ahmad, F. F., Kang, L., Petrone, J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh8005 · Cited by 104
Engela, A. U., Hoogduijn, M. J., Boer, K., Litjens, N. H. R., Betjes, M. G. H., Weimar, W., & Baan, C. C. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12120 · Cited by 103
Schildknecht, A., Brauer, S., Brenner, C., Lahl, K., Schild, H., Sparwasser, T., Probst, H. C., & van den Broek, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910620107 · Cited by 93
“To gain insight into how Treg cells impact on DC-induced peripheral CD8 T cell tolerance, we blocked the action of two molecules that are critically involved in suppression by Treg cells, namely IL-10 and CTLA-4 (21, 22).”
BackgroundImpairment of T Cell Function in Parasitic Infections
Rodrigues, V., Cordeiro‐da‐Silva, A., Laforge, M., Ouaissi, A., Akharid, K., Silvestre, R., & Estaquier, J. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002567 · Cited by 103
“Although anergy is viewed as a process regulating the initial phase of the T cell response, the emergence of regulatory T cells (Tregs) expressing immunomodulatory molecules, such as CTLA4, IDO, or ATP-metabolizing enzymes, during parasite infection may contribute to sustaining T cell anergy during the chronic phase […”
BackgroundIL-2 coordinates IL-2–producing and regulatory T cell interplay
Amado, I. F., Berges, J., Luther, R. J., Mailhé, M.-P., Garcia, S., Bandeira, A., Weaver, C. T., Liston, A., & Freitas, A. A. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20122759 · Cited by 103
“T reg cells have een shown to repress the capacity of antigen-presenting cells to activate other T cells y inhiiting DC maturation and activation via LAG-3 (Huang et al., 2004; Wing et al., 2008) or CTLA-4 dependent mechanisms, which down-regulate CD80 and CD86 expression y dendritic cells (Onishi et al.”
BackgroundInfluentialImmunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
Bamias, G., Delladetsima, I. K., Perdiki, Μ., Siakavellas, S. I., Goukos, D., Papatheodoridis, G., Daikos, G. L., & Gogas, H. J. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1324032 · Cited by 103
“CTLA4 is expressed constitutively by FoxP3+ Tregs and critically affects their anti-inflammatory function (22, 23).”
BackgroundTreg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe, A. E., & Vignali, D. A. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0066 · Cited by 102
“CTLA-4 blockade was initially thought to work on Tregs through either depletion or reduction of suppression (23).”
BackgroundFoxp3+ regulatory T cells, immune stimulation and host defence against infection
Rowe, J. H., Ertelt, J. M., & Way, S. S. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03551.x · Cited by 105
“55, 56 Importantly, whereas CTLA-4 ablation in Foxp3 + cells reproduces some features of Treg-cell deficiency, it does not recapitulate the more rapid onset of fatal systemic autoimmunity in mice with naturally occurring or targeted defects in all Treg cells because of defects in Foxp3.”
BackgroundCTLA-4 expression by B-1a B cells is essential for immune tolerance
Yang, Y., Li, X., Ma, Z., Wang, C., Yang, Q., Byrne-Steele, M. L., Hong, R., Min, Q., Zhou, G., Cheng, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20874-x · Cited by 102
Self-citationThe PI3K p110δ Regulates Expression of CD38 on Regulatory T Cells
Patton, D. T., Wilson, M. D., Rowan, W. C., Soond, D. R., & Okkenhaug, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017359 · Cited by 104
“105 CD252 responder cells and 105 APCs were added to wells of a 96 U-well plate along with 1mg/ml anti-CD3e.”
BackgroundInfluentialGerold, K. D., Zheng, P., Rainbow, D. B., Zernecke, A., Wicker, L. S., & Kissler, S. (2011) · Diabetes · doi:10.2337/db11-0130 · Cited by 102
“In addition, CTLA-4 was found to prevent T lymphocytes from building lasting interactions with antigen-presenting cells (APCs) (14).”
BackgroundResultInfluentialCurrent modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 101
“In the TME it is expressed on tumor cells and on Tregs, both of which can suppress T cell lysis of tumors (Wing et al., 2008).”
BackgroundEskandari, S. K., Sulkaj, I., Melo, M. B., Li, N., Allos, H., Alhaddad, J. B., Kollár, B., Borges, T. J., Eskandari, A. S., Zinter, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4744 · Cited by 101
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart
Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 101
“These mice have a similar phenotype to global CTLA4-knockout mice with early mortality, although with delayed kinetics 18,36 .”
Zhang, S., Ke, X., Zeng, S., Wu, M., Lou, J., Wu, L., Huang, P., Huang, L., Wang, F., & Pan, S. (2015) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.57 · Cited by 95
CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria
Barnes, M. J., Griseri, T., Johnson, A. M. F., Young, W., Powrie, F. M., & Ízcue, A. (2012) · Mucosal Immunology · doi:10.1038/mi.2012.75 · Cited by 101
The Immunogenetic Architecture of Autoimmune Disease
Goris, A., & Liston, A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007260 · Cited by 105
“At the functional level, CTLA4 is a key mechanism by which regulatory T cells suppress disease (Wing et al. 2008), so it is notable that a splice variant of CTLA4 associated with autoimmune diseases has reduced production of a tolerogenic soluble isoform (Ueda et al. 2003).”
BackgroundGastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
Regulatory T cells overturned: the effectors fight back
Walker, L. S. K. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03053.x · Cited by 102
Jochéms, C., Tucker, J. A., Tsang, K.-Y., Madan, R. A., Dahut, W. L., Liewehr, D. J., Steinberg, S. M., Gulley, J. L., & Schlom, J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1524-0 · Cited by 100
Harnessing the biology of regulatory T cells to treat disease
Wardell, C. M., Boardman, D. A., & Levings, M. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01089-x · Cited by 100
“44), IL-10 (ref.”
Next-generation insights into regulatory T cells: expression profiling and FoxP3 occupancy in Human
Birzele, F., Fauti, T., Stahl, H., Lenter, M. C., Simon, E., Knebel, D., Weith, A., Hildebrandt, T., & Mennerich, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr444 · Cited by 84
“Further examples for TREG-mediated T cell suppression of FoxP3 target genes have been described: DAB2 (56), CTLA4 (57) and EBI3 (IL-27/ IL-35) (58).”
BackgroundInfluentialRegulatory T cells induced by B cells: a novel subpopulation of regulatory T cells
Chien, C., & Chiang, B. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0391-3 · Cited by 100
“Studies have demonstrated that ICOS controls IL-10 production and functional CTLA4 expression in Treg cells [73–75].”
InfluentialImmunological Mechanisms in Allergic Diseases and Allergen Tolerance: The Role of Treg Cells
Calzada, D., Baos, S., Cremades‐Jimeno, L., & Cárdaba, B. (2018) · Journal of Immunology Research · doi:10.1155/2018/6012053 · Cited by 101
“These cells could act at the initiation of adequate specific antigenic immune response, promoting tolerogenic DC phenotypes, inhibiting the inflammatory ones [49].”
BackgroundNegative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 101
Onuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
The Defect in Regulatory T Cells in Psoriasis and Therapeutic Approaches
Kanda, N., Hoashi, T., & Saeki, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173880 · Cited by 99
“The suppressive function of Tregs is mediated by multiple mechanisms (Figure 2) [12]; Tregs kill effector T cells or DCs through granzymes [13]; Tregs compete for IL-2 with effector T cells via CD25 and deprive IL-2, thus, inducing apoptosis [14,15]; Tregs release IL-10 and TGF-β, suppressing the proliferation of effe…”
BackgroundStriking a balance: new perspectives on homeostatic dendritic cell maturation
Bosteels, V., & Janssens, S. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01079-5 · Cited by 99
“Through an as yet poorly understood process termed transendocytosis, CTLA4 expressed on T reg cells removes surface expressed CD80 and CD86 from DCs, thereby increasing their threshold to stimulate naive T cells 46,134,135 .”
Human FOXP 3+ T regulatory cell heterogeneity
Mohr, A., Malhotra, R., Mayer, G., Gorochov, G., & Miyara, M. (2018) · Clinical & Translational Immunology · doi:10.1002/cti2.1005 · Cited by 102
“antibodies, and lymphoproliferative disease, in addition to fatal systemic autoimmunity.(54) In humans, for decades, deficiency in CTLA-4 was”
BackgroundSelf-citationInterfaces between cellular responses to DNA damage and cancer immunotherapy
Pilger, D., Seymour, L. W., & Jackson, S. P. (2021) · Genes & Development · doi:10.1101/gad.348314.121 · Cited by 95
“Moreover CTLA-4 expression by Tregs is crucial for their immune suppressive functions, potently binding CD80/CD86 ligands on APCs and therefore preventing T-cell activation (Takahashi et al. 2000; Wing et al. 2008).”
BackgroundMechanisms of immune checkpoint inhibitor-mediated liver injury
Shojaie, L., Ali, M., Iorga, A., & Dara, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.003 · Cited by 98
Immune checkpoint molecules in pregnancy: Focus on regulatory T cells
Zhang, Y., & Sun, H. (2020) · European Journal of Immunology · doi:10.1002/eji.201948382 · Cited by 99
Exosome: A New Player in Translational Nanomedicine
Aheget, H., Tristán-Manzano, M., Mazini, L., Cortijo-Gutierrez, M., Galindo-Moreno, P., Herrera, C., Martin, F., Marchal, J. A., & Benabdellah, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082380 · Cited by 92
“In the murine model, Tregs appear to produce quantitatively more exosomes than naïve CD4 + and CD8 + T cells [147].”
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 99
“Specific deletion of CTLA-4 from Treg also led to systemic lymphoproliferation and death of the mice, albeit with slower kinetics (22).”
BackgroundHarnessing Regulatory T cells to Suppress Asthma
Thorburn, A. N., & Hansbro, P. M. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0342tr · Cited by 98
“Anti–CTLA-4 treatment reverses Treg suppression of effector T cell responses, and CTLA-4–deficient mice have defective Tregs (46, 47).”
BackgroundConfirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis
Carr, E. J., Niederer, H. A., Williams, J., Harper, L., Watts, R. A., Lyons, P. A., & Smith, K. G. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-121 · Cited by 95
“Specific deficiency of Ctla4-/- in natural Foxp3+CD4+ regulatory T cells results in spontaneous autoimmune disease [24].”
BackgroundThe Alternative NF-κB Pathway in Regulatory T Cell Homeostasis and Suppressive Function
Grinberg-Bleyer, Y., Caron, R., Seeley, J. J., De Silva, N. S., Schindler, C. W., Hayden, M. S., Klein, U., & Ghosh, S. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800042 · Cited by 91
“Mice with conditional deletion of Ctla4 in Tregs also develop a severe autoimmune syndrome despite a significant increase in their number of Tregs (45), and we observed reduced CTLA-4 expression by nfkb2 Tregs.”
BackgroundWei, S. C., Sharma, R., Anang, N.-A. A. S., Levine, J. H., Zhao, Y., Mancuso, J. J., Setty, M., Sharma, P., Wang, J., Pe’er, D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.004 · Cited by 97
“…reported that CTLA-4 can act via removal of B7 ligands from APCs (Hou et al., 2015; Qureshi et al., 2011), regulation of T cell motility (Schneider et al., 2006), cell-extrinsic suppression by T regulatory (Treg) cells (Wing et al., 2008), and cell-intrinsic effects on signaling (Lee et al., 1998).”
InfluentialTabares, P., Berr, S., Römer, P. S., Chuvpilo, S., Matskevich, A. A., Tyrsin, D., Fedotov, Y., Einsele, H., Tony, H., & Hünig, T. (2014) · European Journal of Immunology · doi:10.1002/eji.201343967 · Cited by 97
Weiss, L., Letimier, F. A., Carrière, M., Maiella, S., Donkova-Petrini, V., Targat, B., Benecke, A., Rogge, L., & Lévy, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000027107 · Cited by 97
“As expected, many of the genes differentially expressed at week 0 (FOXP3, CTLA4, IL10, FAS, LRRC32 (GARP), CCR8, and IL1R1) have been associated with phenotype or function of Treg (23-26) (Fig.”
BackgroundRegulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche
Cohen, J. N., Gouirand, V., Macon, C. E., Lowe, M. M., Boothby, I. C., Moreau, J. M., Gratz, I. K., Stoecklinger, A., Weaver, C. T., Sharpe, A. H., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adh0152 · Cited by 98
“This result is in contrast to previous studies demonstrating that CTLA-4 on T regs is required to restrain autoimmunity ( 32 , 33 ), suggesting that CTLA-4 is relatively dispensable for T reg - mediated cutaneous immune homeostasis in adult mice.”
ResultWu, C., Rauch, U., Korpos, E., Song, J., Loser, K., Crocker, P. R., & Sorokin, L. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804247 · Cited by 90
“Their generation and function, which is the suppression of the activation and proliferation of the CD4 CD25 effector T cells (Teff) during immune responses, is based on their surface markers like CD127, CD62L, CD103, CD122, CTLA-4, and GITR (3).”
The targeting of immunosuppressive mechanisms in hematological malignancies
Andersen, M. H. (2014) · Leukemia · doi:10.1038/leu.2014.108 · Cited by 97
Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors
Park, H. J., Kusnadi, A., Lee, E.-J., Kim, W. W., Cho, B. C., Lee, I. J., Seong, J., & Ha, S.-J. (2012) · Cellular Immunology · doi:10.1016/j.cellimm.2012.07.001 · Cited by 90
Clavijo, P. E., Moore, E. C., Chen, J., Davis, R. J., Friedman, J., Kim, Y., Van Waes, C., Chen, Z., & Allen, C. T. (2017) · Oncotarget · doi:10.18632/oncotarget.18437 · Cited by 91
“Tregs mediate immunosuppression at least through IL-10 and TGFβ secretion and expression of cell surface cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) [9, 16].”
The application of nanotechnology in immune checkpoint blockade for cancer treatment
Deng, H., & Zhang, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.09.026 · Cited by 98
Foxp3+ Treg cells in humoral immunity
Wing, J. B., & Sakaguchi, S. (2013) · International Immunology · doi:10.1093/intimm/dxt060 · Cited by 98
“In T reg -cell-specific CTLA-4 cKO mice, we have also previously reported hyper-IgE and enhanced IgG in the serum (52) .”
BackgroundSelf-citationMachicote, A., Belén, S., Baz, P., Billordo, L. A., & Fainboim, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02788 · Cited by 98
Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer Therapy
He, M., Yang, T., Wang, Y., Wang, M., Chen, X., Ding, D., Zheng, Y., & Chen, H. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002104 · Cited by 96
Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 98
“, 2000), impairing the upregulation of CD80 and CD86 on DCs and limiting the activation of naive T cells by inhibiting CD28 signaling (Wing et al., 2008).”
BackgroundSchmitt, E. G., Haribhai, D., Williams, J. B., Aggarwal, P., Jia, S., Charbonnier, L.-M., Yan, K., Lorier, R., Turner, A., Ziegelbauer, J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200936 · Cited by 84
The role of regulatory T cells in nervous system pathologies
Duffy, S. S., Keating, B. A., Perera, C. J., & Moalem‐Taylor, G. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24073 · Cited by 97
Costimulation Blockade in Autoimmunity and Transplantation: The CD28 Pathway
Adams, A. B., Ford, M. L., & Larsen, C. P. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601135 · Cited by 95
Regulatory T cells and T helper 17 cells in viral infection
Wan, Z., Zhou, Z., Liu, Y., Lai, Y., Luo, Y., Peng, X., & Zou, W. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12873 · Cited by 96
SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis
Aghbash, P. S., Eslami, N., Shamekh, A., Entezari‐Maleki, T., & Baghi, H. B. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119124 · Cited by 96
“suppressive signals in the regulatory or effector T-cells [48,49].”
Blankenhaus, B., Klemm, U., Eschbach, M.-L., Sparwasser, T., Huehn, J., Kühl, A. A., Loddenkemper, C., Jacobs, T., & Breloer, M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001920 · Cited by 80
“the diversity of mechanisms that Tregs use to suppress immune responses, such as the induction of apoptosis by the injection of cAMP, the killing via granzymes, the release of IL-10 and TGF-b, in which CTLA-4–mediated signaling is one out of several (3, 47).”
BackgroundAntunes, I., & Kassiotis, G. (2010) · Journal of Virology · doi:10.1128/jvi.01559-10 · Cited by 96
“In contrast, the conditional ablation of CTLA-4 in Treg cells has been reported to cause systemic inflammatory manifestations (68).”
BackgroundKersten, K., Salvagno, C., & de Visser, K. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00516 · Cited by 89
“In addition to its role in T cell priming, CTLA-4 also regulates the suppressive function of tumor-infiltrating Tregs (36, 37).”
BackgroundBreakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and Humans
Jeker, L. T., Bour-Jordan, H., & Bluestone, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007807 · Cited by 96
“Of note, CTLA-4 is also critical for the function of regulatory T cells (Tregs) (Fife and Bluestone 2008; Wing et al. 2008; Bour-Jordan and Bluestone 2009), but the scaCTLA-4 Tg protected Treg-deficient NODB7-1/2KO mice from diabetes as well, showing an autoreactive conventional T-cell intrinsic…”
BackgroundThe immunosuppressive microenvironment and immunotherapy in human glioblastoma
Zhang, X., Zhao, L., Zhang, H., Zhang, Y., Ju, H., Wang, X., Ren, H., Zhu, X. G., & Dong, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1003651 · Cited by 95
“Tregs represent a subset of CD4 T lymphocytes, which are mainly characterized by high expression of the transcription factors Foxp3, CD25, and cytotoxic T lymphocyte antigen 4 (CTLA-4), with Foxp3 controlling the expression of CTLA-4 in Tregs (23, 24).”
BackgroundShi, W. M., Wang, Y., Zhao, Y., Kim, J. J., Li, H., Meng, C., Chen, F., Zhang, J., Mak, D. H. F., Van, V., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adf6724 · Cited by 94
Costimulatory pathways in transplantation
Pilat, N., Sayegh, M. H., & Wekerle, T. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.04.002 · Cited by 94
“Further development seems uncertain [28] in articular in view of CTLA4’s role in the induction of peripheral olerance [41].”
BackgroundThe glomerular permeability factors in idiopathic nephrotic syndrome
Davin, J. C. (2015) · Pediatric Nephrology · doi:10.1007/s00467-015-3082-x · Cited by 94
“CD80 expression on dendritic cells is inhibited by cytotoxic T-lymphocyte-associated-protein 4 (CTLA-4) and IL-10, which are produced by T regulatory (Treg) cells [70, 71].”
BackgroundPituch, K. C., Miska, J. M., Krenciute, G., Panek, W. K., Li, G., Rodríguez-Cruz, T., Wu, M., Han, Y., Lesniak, M. S., Gottschalk, S. M., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.001 · Cited by 94
.Robertson, C. C., & Rich, S. S. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.01.006 · Cited by 73
The role of FOXP3+ regulatory T cells in human autoimmune and inflammatory diseases
Mohr, A., Atif, M., BALDERAS, R. S., Gorochov, G., & Miyara, M. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13288 · Cited by 94
Self-citationBoth PD-1 Ligands Protect the Kidney from Ischemia Reperfusion Injury
Jaworska, K., Ratajczak, J., Huang, L., Whalen, K., Yang, M., Stevens, B. K., & Kinsey, G. R. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400497 · Cited by 95
Ménétrier‐Caux, C., Curiel, T. J., Faget, J., Manuel, M., Caux, C., & Zou, W. (2012) · Targeted Oncology · doi:10.1007/s11523-012-0208-y · Cited by 95
“However, their in vitro neutralization is not sufficient to block nTreg suppression, whereas it plays a role at least in part in the in vivo effect of Treg in the inhibition of autoimmune inflammatory bowel disease (IBD), and in some iTreg.”
Canani, R. B., Terrin, G., Cardillo, G., Tomaiuolo, R., & Castaldo, G. (2010) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3181d135ef · Cited by 93
Trogocytosis of CD80 and CD86 by induced regulatory T cells
Gu, P., Gao, J. F., D’Souza, C. A., Kowalczyk, A., Chou, K., & Zhang, L. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2011.62 · Cited by 93
Induction of peripheral CD4+ T‐cell tolerance and CD8+ T‐cell cross‐tolerance by dendritic cells
Lutz, M. B., & Kurts, C. (2009) · European Journal of Immunology · doi:10.1002/eji.200939548 · Cited by 93
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models
Jure‐Kunkel, M., Masters, G. R., Girit, E., Dito, G., Lee, F. Y., Hunt, J. T., & Humphrey, R. W. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1451-5 · Cited by 93
“CTLA-4, which has a higher affinity for binding B7 molecules than does CD28, curtails T-cell activation and proliferation by various mechanisms, including competitive inhibition of CD28, delocalization of protein kinase C-theta and CARMA1 from the immune synapse, transendocytosis of B7, and modulation of regulatory T-…”
BackgroundMichels, A. W., Zhang, L., Khadra, A., Kushner, J. A., REDONDO, M. J., & Pietropaolo, M. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12299 · Cited by 94
The battle against immunopathology: infectious tolerance mediated by regulatory T cells
Gravano, D. M., & Vignali, D. A. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0907-z · Cited by 94
“However, TH17 cells remaining in the small intestine acquired a suppressive phenotype that could be abrogated by blocking the IL10, CTLA-4, and TGF-b pathways simultaneously.”
BackgroundInfluentialTumor regulation of the tissue environment in the liver
Eggert, T., & Greten, T. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.005 · Cited by 94
“Anti-CTLA-4 antibodies do not only disinhibit CTL, but also restrain the suppressive abilities of CTLA-4 expressing T reg.”
InfluentialInhibition of Nr4a Receptors Enhances Antitumor Immunity by Breaking Treg-Mediated Immune Tolerance
Hibino, S., Chikuma, S., Kondo, T., Ito, M., Nakatsukasa, H., Omata-Mise, S., & Yoshimura, A. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3102 · Cited by 87
“Previous research demonstrated that intratumoral Tregs suppress co-stimulatory signals from antigen-presenting cells (APCs) by CTLA-4-mediated trans-endocytosis of B7-molecules CD80/CD86, which in turn suppress CD8 + CTL effector function (3,23-25).”
BackgroundCheng, M., & Anderson, M. S. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-074953 · Cited by 93
Photodynamic Therapy and Immune Checkpoint Blockade†
Cramer, G. M., Moon, E. K., Cengel, K. A., & Busch, T. M. (2020) · Photochemistry and Photobiology · doi:10.1111/php.13300 · Cited by 93
“CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is an immune checkpoint receptor constitutively expressed in Tregs and upregulated in other activated T cells (11).”
BackgroundOnodera, T., Jang, M. H., Guo, Z., Yamasaki, M., Hirata, T., Bai, Z., Tsuji, N. M., Nagakubo, D., Yoshie, O., Sakaguchi, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804116 · Cited by 92
“2D (left), Ctla4 Foxp3 mice, whose Tregs are selectively deficient in CTLA-4 expression (27), exhibited an 50% reduction in IDO CD11c DCs compared with the level in wild-type control mice, although the extent of the geographical association between Tregs and DCs in the MLNs was comparable to that seen in wild-type mic…”
BackgroundMethodResultSelf-citationCutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells
Wang, C. J., Kenefeck, R., Wardzinski, L., Attridge, K., Manzotti, C., Schmidt, E. M., Qureshi, O. S., Sansom, D. M., & Walker, L. S. K. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200972 · Cited by 85
“In contrast, naturally controlled expression of CTLA-4 in Tconv (in mice lacking CTLA-4 specifically in Treg) was only able to extend the lifespan by a few weeks (16).”
BackgroundSchneidawind, D., Pierini, A., & Negrin, R. S. (2013) · Blood · doi:10.1182/blood-2013-08-453126 · Cited by 93
“Several studies showed that IL-10, transforming growth factor b (TGF-b), and IL-35 have been implicated in enhancing suppression(8-12); whereas CTLA-4, LAG-3, CD39, and granzymes play an important role in the contact-dependent immune control.(13-18) The ability of Tregs to suppress effector cell proliferation and func…”
Lee, S. E., Li, X., Kim, J. C. K., Lee, J., González-Navajas, J. M., Hong, S. H., Park, I., Rhee, J. H., & Raz, E. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.03.042 · Cited by 92
T helper 17 cells: discovery, function, and physiological trigger
Torchinsky, M. B., & Blander, J. M. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0248-3 · Cited by 92
“The role of CTLA-4 in Treg cells has been recently confirmed in a study where selective ablation of this marker resulted in spontaneous lymphoproliferation and fatal T cell-mediated autoimmune disease due to a loss of function in the Treg cells, particularly in their ability to downregulate CD80 and CD86 on DC [92].”
BackgroundChen, J., Ganguly, A., Mucsi, A. D., Meng, J., Yan, J., Detampel, P., Munro, F., Zhang, Z., Wu, M. L., Hari, A., et al. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160620 · Cited by 92
“Constitutively expressed by T reg cells, CTLA-4 has been shown to be important for DC-targeted suppression in BALB/c mice, a conclusion drawn exclusively from analyses of antigen-specific T reg cells (Wing et al., 2008; Qureshi et al., 2011).”
BackgroundPost-Translational Regulations of Foxp3 in Treg Cells and Their Therapeutic Applications
Dong, Y. W., Yang, C., & Pan, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626172 · Cited by 93
Engineered cell entry links receptor biology with single-cell genomics
Yu, B., Shi, Q., Belk, J. A., Yost, K. E., Parker, K. R., Li, R., Liu, B. B., Huang, H., Lingwood, D., Greenleaf, W. J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.11.016 · Cited by 75
Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion
Lamarche, C., Ward‐Hartstonge, K. A., Tian, M., Lin, D. T. S., Huang, Q. B., Brown, A., Edwards, K., Novakovsky, G., Qi, C. N., Kobor, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2219086120 · Cited by 93
“For example, CTLA-4 is essential for Treg function (63) and TIM-3 + Tregs are more potent than their TIM-3 − counterparts in vitro (61, 64).”
Zhang, T., Fresnay, S., Welty, E. E., Sangrampurkar, N., Rybak, E., Zhou, H., Cheng, X., Feng, Q., Avon, C., Laaris, A., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03624.x · Cited by 92
“Moreover, CTLA4 controls Tregs function (5,34), and natural Tregs critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells (23).”
BackgroundPoirier, N., Dilek, N., Mary, C., Ville, S., Coulon, F., Branchereau, J., Tillou, X., Charpy, V., Pengam, S., Nerrière‐Daguin, V., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12964 · Cited by 91
“Instead, FR104 seems to favor Treg induction and/or accumulation since we observed in the blood and in the graft an accumulation of Helios-negative cells expressing Foxp3 and CTLA-4, a phenotype associated with the suppressive function of Tregs (54) and peripheral induced Tregs (55,56).”
BackgroundKim, M. J., Kim, K., Park, H. J., Kim, G.-R., Hong, K. H., Oh, J. H., Son, J., Park, D. J., Kim, D., Choi, J.-M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-022-01373-1 · Cited by 90
Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer
Feng, C. H., Mell, L. K., Sharabi, A. B., McHale, M. T., & Mayadev, J. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.05.003 · Cited by 90
Tumour immunotherapy: lessons from predator–prey theory
Hamilton, P. T., Anholt, B. R., & Nelson, B. H. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00719-y · Cited by 90
Yang, S. J., Singh, A. K., Drow, T., Tappen, T., Honaker, Y., Barahmand-pour-Whitman, F., Linsley, P. S., Cerosaletti, K. M., Mauk, K. E., Xiang, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1716 · Cited by 92
Tumor Regulatory T Cells Potently Abrogate Antitumor Immunity
Liu, Z., Kim, J. H., Falo, L. D., & You, Z. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802664 · Cited by 91
“A recent report indicates that naive Treg in vitro down-regulate CD80 or CD86 expression on splenic DC at a ratio of 1:10 (DC:Treg) (39).”
BackgroundChattopadhyay, G., & Shevach, E. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301693 · Cited by 91
“phoproliferation and fatal T cell–mediated autoimmune disease (10).”
BackgroundResultT Regulatory Cell Biology in Health and Disease
Alroqi, F. J., & Chatila, T. A. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0606-9 · Cited by 96
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.